IN RE: Application of: Michael L. KING

For: Tubular Nozzles for Use in Systems for Delivering Medicaments

Serial No.: 10/533,206

Confirmation No.: 9099

Filing Date: April 28, 2005

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the

Art Unit: 3772

Examiner: Nihir B. Patel

Ex	aminer a	nd officially made of record in accordance with the provisions of 37 CFR 1.97.
	[] Co [] A sul	pies of the following references are enclosed: Reference Nos. 9-20 pies of the references were submitted in parent application
A.	[] OR	The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office Action on the merits, whichever event occurs last. 37 CFR 1.97(b).
	OK	
	[]	The Information Disclosure Statement submitted herewith is being filed before the mailing of a first Office Action after the filing of a Request for Continued Examination under 37 CFR 1.114 (37 CFR 1.97(b)(4)).
В.	[X]	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in §1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either: (1) a final Action under §1.113 or (2) a Notice of Allowance under §1.311, whichever occurs first.
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
	[X]	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under §1.97(c) (\$180.00).

Atty. Docket No. PU4891USw

C. []	The Information Disclosure Statement transmitted herewith is being filed after a final Action under \$1.113, or a Notice of Allowance under \$1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which issued on International Publication No	
In accordance with the requirements of 37 CFR 1.97(d):		
[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]	
[]	Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; and	
[]	The petition fee set forth in §1.17(i)(1) (\$180.00) is submitted herewith.	
[X] Please charge any required fees to Deposit Account No. <u>07-1392</u> . [] A duplicate copy of this paper is attached.		
	Respectfully submitted, Minus J. Michael Strickland	

Artorney for Applicant Registration No. 47,115

Date: January 11, 2008 Customer No. 23 347 GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709-3398

Telephone: (919) 483-9024 Facsimile: (919) 483-7988